Molecular Medicine Tri-Conference 2017
Visit Q2 Solutions, meet our Experts and attend our Sessions on February 21 on NGS Assay Development and Validation and NGS Assays in Oncology
About This EventPlease plan to attend our presentations listed below.
Title: NGS Assay Development and Validation
Speaker: Patrick Hurban, Ph.D.
Date and Time: Feb 21, 2017 at 10:45 am
Abstract: Genomic analysis permeates clinical development, with demonstrated utility at all points along the continuum from discovery to diagnostics. Manifold sample types and testing requirements, as well as evolving needs, pose significant challenges. Specific use cases will be presented to demonstrate how these challenges can be overcome, and why a diverse toolkit enhances the likelihood of success.
Title: NGS Assays in Oncology
Speaker: Patrick Hurban, Ph.D.
Date and Time: Feb 21, 2017 at 2:00 pm
Session Chair with opening remarks
Title: Leveraging Genomics-Based Assays for Immuno-Oncology in Clinical Research
Speaker: Victor Weigman
Date and Time: Tuesday, February 21, 2017 at 12:55 PM
Abstract: This talk will outline results from genomic profiling of immune signatures (B/T cell repertoire, IGVH, HLA) for biomarker identification in multiple cancer indications with comparisons to existing clinical research assays.
Short Course Title: Flow Cytometry and Phenotypic Cell Analysis in Immuno-Oncology
Speakers: Mark Edinger and Alistair J. Watt, Ph.D.
Date and Time: Feb 20, 2017 at 8:00-11:00 am
Presentation invitation by Medimmune
Poster Presentation: HLAProfiler: A Novel, Allele Sequence Signature Approach Enabling HLA-Typing for Biomarker Identification in Gene Expression Data
Authors: Chad Brown and Martin Buchkovich
Senior Director and Global Head, Translational Genomics
Patrick Hurban, Ph.D. is senior director and global head of Translational Genomics at Q2 Solutions. In this role, he is responsible for the identification and implementation of new genomic capabilities, encompassing bioinformatics and wet-laboratory methods, as well as the development and validation of genomic assays to support research and clinical programs. These include broad-based screening assays, such as exome and RNA sequencing, to highly focused expression, genotyping and sequencing assay panels that target a smaller number of genes.
Dr. Hurban has more than 25 years of experience in molecular genetics, including more than 18 years in positions of increasing responsibility in high-profile genomics-focused organizations. His research interests have focused on the genetic control of gene expression and have spanned diverse fields such as toxicology, developmental, and cancer biology.
Following a Bachelor’s degree in Biology from the University of North Carolina at Chapel Hill, he earned his Ph.D. in Human Genetics from the University of Utah in Salt Lake City before serving as a postdoctoral research fellow of the American Cancer Society in the Department of Developmental Biology at Stanford University.
Director, Translational Genomics
Dr. Victor Weigman, Ph.D. is Director, Translational Genomics at Q2 Solutions, a Quintiles Quest Joint Venture, leading the group with a goal of continued facilitation of pre-clinical drug development through biomarker identification. Ongoing research revolves around the genomic profiling of solid tumors from both DNA and RNA approaches including the development of robust assays that can be leveraged as laboratory developed tests.
Dr. Weigman brings more than 10 years of biomarker discovery research with genomics, with a majority of them dedicated to Expression Analysis (EA), a Q2 Solutions Company. He has published 14 papers on biomarker identification and assay development and has contributed to the development and launch of several genomic CLIA Assays. Additionally, Dr. Weigman is involved in pharma partnerships for clinical trial development using genomic profiling technologies.
Dr. Weigman obtained his Ph.D. at the University of North Carolina in Biology and Bioinformatics within the Lineberger Comprehensive Cancer Center.
Scientific Advisor, Flow Cytometry
Mark Edinger is the scientific advisor for Flow Cytometry at Q2 Solutions. As the scientific advisor, Mark is responsible for flow cytometry assay design and implementation. He works with both the Translational Biomarkers Laboratory to develop assays and the Global Cytometry Group to produce assays, and is the architect of the systems and workflows used in Q2 Solutions’ flow cytometry assay development and production laboratories.
Mark began his career at the Cleveland Clinic Foundation, a preeminent medical institution, where he pioneered flow cytometry in the late 1970s, building both clinical and research core flow cytometry laboratories. During his 21 years at the Cleveland Clinic, Mark developed many of the techniques and assays employed today for clinical practice and academic research. During this time, Mark also was a consultant for Becton Dickinson (BD) Immunocytometry Systems and participated in clinical trials of new BD products. In 1998, Mark formally joined BD where he founded the Technical Applications Group, and later the R&D Systems Validation Laboratory. While at BD, Mark, working with scientists at Amgen, developed the whole blood phosphoprotein lysing buffer that is now used daily in laboratories throughout the world. Mark joined Quintiles in 2012 and has been part of a collaboration which introduced the quantitative standardization of flow cytometers, along with other state of the art practices, making Quintiles flow laboratories the first to offer this level of instrument standardization anywhere in the world. Mark became part of the Q2 Solutions team when the company was officially launched in June 2015 as a result of a Quintiles and Quest Diagnostics joint venture.
Mark graduated from Case Western Reserve University with a Bachelor of Science degree in Biology.
Director, Translational Science Laboratory, Europe
Alistair Watt, Ph.D. is the Director of the Translational Science Laboratory (ADL) in Europe and is based in Edinburgh, Scotland. He has significant experience in the development of flow cytometry, ELISA and Molecular Biology assays for clinical trials. Before joining Q2 Solutions, Dr. Watt was a Senior Post-Doctoral Fellow at the University of Edinburgh working on a European Union Framework 6 project to define the conditions necessary for controlled embryonic cell differentiation to multiple cell types. In this role, he mentored Ph.D. students and produced coursework and taught undergraduates. From 2000-2003, Dr. Watt worked at the Medical College of Wisconsin, Milwaukee. He was awarded an American Heart Association Post-Doctoral fellowship to study the transcriptional control of heart development leading to a number of high profile publications. Dr. Watt received his Ph.D. from the University of Edinburgh in 1999 for work on liver development as a model for tissue formation and differentiation.